MedTrace Logo

Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

NCT05053308 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-08-07

No results posted yet for this study

Summary

Proportional dose of sublingual fentanyl tablet (Narco®) based on daily opioid requirement versus intravenous PCA for breakthrough cancer pain: A prospective, randomized, open-label, noninferiority trial.

Conditions

  • Cancer Pain
  • Breakthrough Pain

Interventions

DRUG

Intravenous Infusion

IV PCA(fentanyl) Fentanyl bolus = MME \* 15%

DRUG

Sublingual Tablet

subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.

Sponsors & Collaborators

  • Seoul National University

    lead OTHER

Principal Investigators

  • Jee Youn Moon, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-05-31
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05053308 on ClinicalTrials.gov